Punch & Associates Investment Management Inc. Purchases New Position in iRadimed Corporation $IRMD

Punch & Associates Investment Management Inc. purchased a new stake in shares of iRadimed Corporation (NASDAQ:IRMD) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 20,000 shares of the medical equipment provider’s stock, valued at approximately $1,911,000. Punch & Associates Investment Management Inc. owned approximately 0.16% of iRadimed at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Quarry LP purchased a new stake in shares of iRadimed during the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC increased its position in iRadimed by 827.1% in the fourth quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider’s stock worth $43,000 after purchasing an additional 397 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in iRadimed by 191.1% during the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider’s stock valued at $45,000 after purchasing an additional 495 shares in the last quarter. CWM LLC raised its stake in iRadimed by 19.5% during the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider’s stock valued at $64,000 after purchasing an additional 107 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new position in iRadimed during the second quarter valued at $84,000. Institutional investors own 92.34% of the company’s stock.

iRadimed Trading Down 0.5%

iRadimed stock opened at $87.47 on Thursday. iRadimed Corporation has a 12-month low of $67.84 and a 12-month high of $107.90. The firm has a 50-day moving average price of $93.16 and a 200-day moving average price of $94.29. The firm has a market capitalization of $1.12 billion, a PE ratio of 48.87 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last issued its quarterly earnings results on Friday, July 31st. The medical equipment provider reported $0.46 EPS for the quarter, beating the consensus estimate of $0.44 by $0.02. The company had revenue of $20.47 million for the quarter, compared to the consensus estimate of $20.35 million. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. As a group, sell-side analysts predict that iRadimed Corporation will post 1.98 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, August 28th. Stockholders of record on Friday, August 14th will be issued a $0.20 dividend. This represents a $0.80 annualized dividend and a dividend yield of 0.9%. The ex-dividend date is Friday, August 14th. iRadimed’s dividend payout ratio is presently 44.69%.

Insider Activity

In related news, CEO Roger E. Susi sold 2,500 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the sale, the chief executive officer directly owned 2,162,500 shares of the company’s stock, valued at approximately $195,922,500. This trade represents a 0.12% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 34.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wall Street Zen cut shares of iRadimed from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. Weiss Ratings cut shares of iRadimed from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, August 3rd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $120.00.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.